Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 21;13(1):20-25.
doi: 10.1002/cld.793. eCollection 2019 Jan.

What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?

Neil Mehta  1 , Francis Y Yao  1
Affiliations
Review

What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma?

Neil Mehta et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Approach to the selection of patients with HCC for LT.
See this image and copyright information in PMC

References

    1. Berry K, Ioannou GN. Comparison of liver transplant‐related survival benefit in patients with versus without hepatocellular carcinoma in the United States. Gastroenterology 2015;149:669‐680; quiz e15–e16. - PubMed
    1. Lai Q, Vitale A, Iesari S, et al. Intention‐to‐treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology 2017;66:1910‐1919. - PubMed
    1. Mehta N, Dodge JL, Goel A, et al. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transpl 2013;19:1343‐1353. - PMC - PubMed
    1. Mehta N, Sarkar M, Dodge J, et al. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions. Transpl 2017;101(Suppl. 2):162‐163. - PMC - PubMed
    1. Mehta N, Heimbach J, Harnois DM, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017;3:493‐500. - PMC - PubMed